@article{oai:nagoya.repo.nii.ac.jp:00024698,
 author = {Nagai, Hirokazu and Fukano, Reiji and Sekimizu, Masahiro and Kada, Akiko and Saito, Akiko M. and Asada, Ryuta and Mori, Tetsuya},
 issue = {3},
 journal = {Nagoya Journal of Medical Science},
 month = {Aug},
 note = {Currently, a standard therapy has not been established for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. While there are many treatment options, such as hematopoietic stem cell transplantation, patients with resistant disease to conventional chemotherapies have particularly poor prognosis. There is urgent need to develop new drugs because of the lack of a standard therapy and poor prognoses. This phase II trial is designed for evaluating the efficacy and safety of alectinib hydrochloride for patients with recurrent or refractory anaplastic lymphoma kinase -positive anaplastic large cell lymphoma. The primary endpoint is the response rate according to the Revised Response Criteria for Malignant Lymphoma. The secondary endpoints are pharmacokinetics, safety in children, complete response rate, response duration, progression-free survival, event-free survival, overall survival, and adverse events. The results of this trial will be the pivotal data for the drug approval of alectinib hydrochloride for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.},
 pages = {407--413},
 title = {Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma : study protocol for a non-randomized non-controlled trial},
 volume = {79},
 year = {2017}
}